Current setbacks cannot prevent gene-editing companies from advancing closer to “one-and-done” cures and new products.

About 150 people in Singapore have transthyretin amyloid cardiomyopathy. Read more at straitstimes.com. Read more at ...

The mood at the annual meeting of the American Society of Cell and Gene Therapy isn’t amazing. The biotech market has been ...

In a new study published in Cell Reports, researchers at the University of Freiburg reveal how a disordered protein segment ...

Danforth Technology Company launched Spearhead Bio to make the process of gene editing faster and more efficient.

Leading trade organizations representing the makers of cell and gene therapies are calling for a 10-year moratorium on ...

The University of Bayreuth's Biomaterials research group has, for the first time, successfully applied the CRISPR-Cas9 ...

Potential best-in-class extrahepatic in vivo gene editing with all-in-one delivery to the central nervous system (CNS) is a ...

CRISPR Therapeutics benefits from Casgevy’s approval and a deep pipeline, despite early rollout hurdles and cost challenges.

At stake in the ongoing patent dispute over the gene-editing tool are rights to the most important new biotechnology of the ...

Stylus will use the Eli Lilly and J&J-backed funds to advance its in vivo genetic medicines platform and develop its pipeline ...

Stylus Medicine is unsheathing, penning a mission to develop next-gen in vivo genetic medicines with $85 million in hand, ...